Unveiling changes in the landscape of patient populations in cancer early drug development

about

Unveiling changes in the landscape of patient populations in cancer early drug development

Item

http://www.wikidata.org/entity/Q28073826

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Unveiling changes in the lands ...... cancer early drug development

@ast

Unveiling changes in the lands ...... cancer early drug development

@en

Unveiling changes in the lands ...... cancer early drug development

@nl

type

Item

label

Unveiling changes in the lands ...... cancer early drug development

@ast

Unveiling changes in the lands ...... cancer early drug development

@en

Unveiling changes in the lands ...... cancer early drug development

@nl

prefLabel

Unveiling changes in the lands ...... cancer early drug development

@ast

Unveiling changes in the lands ...... cancer early drug development

@en

Unveiling changes in the lands ...... cancer early drug development

@nl

P1476

Unveiling changes in the lands ...... cancer early drug development

@en

P2093

Analía Azaro

http://www.w3.org/2001/XMLSchema#string

Cinta Hierro

http://www.w3.org/2001/XMLSchema#string

Elena Elez

http://www.w3.org/2001/XMLSchema#string

Guillem Argilés

http://www.w3.org/2001/XMLSchema#string

Jordi Rodon

http://www.w3.org/2001/XMLSchema#string

Patricia Gómez

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

P304

14158-14172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.13258

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Joan Carles Galcerán

P5008

ScienceSource

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27835915

http://www.w3.org/2001/XMLSchema#string

P921

Aillse

biomedical investigative technique

P932

5355170

http://www.w3.org/2001/XMLSchema#string